SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.84+1.8%Dec 19 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (4385)8/1/2001 1:45:19 AM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
<<Any chance Novartis could "donate" some of their Ritalin quota? (I would guess not).>>

I think that they can do it. Quote is for racemic methylphenidate, so Novartis will need to transfer their quota to CELG.(quotes are based on early year sale, and overall growth perspective)

Thanks for CELG milestones data.
Regards the manufacturing cost, it will be higher so to keep margin ratio (+)-R sale price should be at premium versus MR-R.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News